Selexipag

司来帕格

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameSelexipag
Drug Alias NameSelexipagum司来帕格塞乐西帕舍来昔帕赛乐西帕 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstanoid IP receptor agonists
TargetsProstanoid IP receptor
Therapy Area/IndicationsChronic thromboembolic pulmonary hypertensionSarcoidosisPulmonary Arterial Hypertension +[5] 
Global Approved IndicationsPulmonary Arterial Hypertension
Approved Indications in ChinaPulmonary Arterial Hypertension
Original Approved Country/TerritoryUnited States
Original Approved Date2015/12/21
Country/TerritoryCzechiaBelgiumBulgaria +[49] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNippon Shinyaku Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesActelion Pharmaceuticals Us IncJohnson & Johnson (China) Investment LtdJanssen-Cilag International Nv +[9] 
Inactive CompaniesExcella GmbhActelion Pharmaceuticals Trading Shanghai Co Ltd
Active IndicationsChronic thromboembolic pulmonary hypertensionPulmonary Arterial HypertensionHypertension, Pulmonary
Inactive IndicationsSarcoidosisCREST Syndrome

Other Information

ATC CodeB01AC27
Related LinksWikipediaDrugBankKEGG